| Entry |
|
|---|
| Name |
Bezuclastinib (USAN/INN) |
|---|
| Formula |
C19H17N5O
|
|---|
| Exact mass |
331.1433
|
|---|
| Mol weight |
331.37
|
|---|
| Structure |
|
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
|
|---|
| Efficacy |
Antineoplastic, Receptor tyrosine kinase inhibitor |
|---|
| Target |
|
|---|
| Pathway |
| hsa05230 | Central carbon metabolism in cancer |
|
|---|
| Interaction |
|
|---|
| Brite |
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
D12600 Bezuclastinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
PDGFR family
KIT* (CD117) [HSA_VAR:3815v1]
D12600 Bezuclastinib (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 25
1 C8x C 15.1200 -11.0600
2 C8y C 15.1200 -12.4600
3 C8x C 16.3324 -13.1600
4 C8y C 17.5449 -12.4600
5 C8y C 17.5449 -11.0600
6 N5x N 16.3324 -10.3600
7 C8x C 18.8764 -12.8926
8 C8y C 19.6993 -11.7600
9 N4x N 18.8764 -10.6274
10 C8y C 21.0700 -11.7600
11 C8x C 21.7700 -12.9724
12 C8x C 23.1700 -12.9724
13 C8x C 23.8700 -11.7600
14 C8x C 23.1700 -10.5476
15 C8x C 21.7700 -10.5476
16 N1b N 13.9076 -13.1600
17 C5a C 12.7121 -12.4696
18 C8y C 11.5247 -13.1551
19 O5a O 12.7120 -11.0603
20 N5x N 10.2016 -12.7834
21 N4x N 9.4360 -13.9255
22 C8y C 10.2855 -15.0065
23 C8y C 11.5761 -14.5326
24 C1a C 12.7329 -15.3088
25 C1a C 9.9106 -16.3276
BOND 28
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 4 7 1
8 7 8 2
9 8 9 1
10 5 9 1
11 8 10 1
12 10 11 2
13 11 12 1
14 12 13 2
15 13 14 1
16 14 15 2
17 10 15 1
18 2 16 1
19 16 17 1
20 17 18 1
21 17 19 2
22 18 20 2
23 20 21 1
24 21 22 1
25 22 23 2
26 18 23 1
27 23 24 1
28 22 25 1
|
|---|
